PMID- 34485159
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210907
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Type 2 Diabetes Mellitus Intersects With Pancreatic Cancer Diagnosis and 
      Development.
PG  - 730038
LID - 10.3389/fonc.2021.730038 [doi]
LID - 730038
AB  - The relationship between type 2 diabetes mellitus (T2DM) and pancreatic cancer 
      (PC) is complex. Diabetes is a known risk factor for PC, and new-onset diabetes 
      (NOD) could be an early manifestation of PC that may be facilitate the early 
      diagnosis of PC. Metformin offers a clear benefit of inhibiting PC, whereas 
      insulin therapy may increase the risk of PC development. No evidence has shown 
      that novel hypoglycemic drugs help or prevent PC. In this review, the effects of 
      T2DM on PC development are summarized, and novel strategies for the prevention 
      and treatment of T2DM and PC are discussed.
CI  - Copyright (c) 2021 Duan, Wang, Pan and Guo.
FAU - Duan, Xiaoye
AU  - Duan X
AD  - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 
      China.
AD  - Graduate School of Peking Union Medical College, Chinese Academy of Medical 
      Sciences, Beijing, China.
FAU - Wang, Weihao
AU  - Wang W
AD  - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 
      China.
FAU - Pan, Qi
AU  - Pan Q
AD  - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 
      China.
FAU - Guo, Lixin
AU  - Guo L
AD  - Department of Endocrinology, Beijing Hospital, National Center of Gerontology, 
      Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 
      China.
AD  - Graduate School of Peking Union Medical College, Chinese Academy of Medical 
      Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210816
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8415500
OTO - NOTNLM
OT  - hyperglycemia
OT  - hypoglycemic therapy
OT  - insulin resistance
OT  - pancreatic cancer
OT  - screening strategy
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The handling editor and the reviewer (YL) declared a shared 
      affiliation with the authors at time of review.
EDAT- 2021/09/07 06:00
MHDA- 2021/09/07 06:01
PMCR- 2021/01/01
CRDT- 2021/09/06 06:06
PHST- 2021/06/24 00:00 [received]
PHST- 2021/07/30 00:00 [accepted]
PHST- 2021/09/06 06:06 [entrez]
PHST- 2021/09/07 06:00 [pubmed]
PHST- 2021/09/07 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.730038 [doi]
PST - epublish
SO  - Front Oncol. 2021 Aug 16;11:730038. doi: 10.3389/fonc.2021.730038. eCollection 
      2021.